| Verrica Pharmaceuticals, Inc. (VRCA) Q1 2025 Corporate Update Conference Call |
Verrica Pharmaceuticals, Inc. (NASDAQ:VRCA ) Q1 2025 Corporate Update Conference Call May 13, 2025 4:30 PM ET Company Participants Kevin Gardner - Managing Director LifeSci Advisors Jayson Rieger - President and CEO John Kirby - Interim CFO Conference Call Participants Stacy Ku - TD Cowen Gregory Renza - RBC Capital Markets Serge Belanger - Needham and Company Kemp Dolliver - Brookline Capital Markets Operator Good evening, ladies and gentlemen, and welcome to the Verrica Pharmaceuticals' First Quarter 2025 Corporate Update Conference Call. At this time, all participants are in a listen-only mode. |
seekingalpha.com |
2025-05-13 22:33:37 |
Czytaj oryginał (ang.) |
| Verrica Pharmaceuticals Inc. (VRCA) Reports Q1 Loss, Tops Revenue Estimates |
Verrica Pharmaceuticals Inc. (VRCA) came out with a quarterly loss of $0.10 per share versus the Zacks Consensus Estimate of a loss of $0.14. This compares to loss of $0.38 per share a year ago. |
zacks.com |
2025-05-13 22:30:37 |
Czytaj oryginał (ang.) |
| Verrica Pharmaceuticals Reports Quarterly 2025 Financial Results |
– Company reports $3.4 million in YCANTH revenue, reflective of increasing demand, following the dispensing of more than 10,000 applicator units in the quarter, the most in company history and a 16.7% growth over Q4'24 – – Late-stage pipeline continues to advance with completion of end-of-Phase 2 meeting with Food and Drug Administration for VP-315, Verrica's candidate for basal cell carcinoma, and continued advancement towards initiation of global Phase 3 program in common warts (VP-102/YCANTH) with partner Torii Pharmaceutical – – Conference call scheduled for today at 4:30 pm ET – WEST CHESTER, Pa., May 13, 2025 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics company developing and selling medications for skin diseases requiring medical interventions, today announced financial results for the quarter ended March 31, 2025. |
globenewswire.com |
2025-05-13 20:05:00 |
Czytaj oryginał (ang.) |
| Verrica Pharmaceuticals to Report First Quarter 2025 Financial Results and Provide a Corporate Update on May 13, 2025 |
WEST CHESTER, Pa., May 07, 2025 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or “the Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that it will host a conference call and live webcast at 4:30 p.m. |
globenewswire.com |
2025-05-07 12:00:00 |
Czytaj oryginał (ang.) |
| Verrica Pharmaceuticals to Participate in the Citizens Life Sciences Conference in New York |
WEST CHESTER, Pa., April 30, 2025 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or “the Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that Jayson Rieger, PhD, MBA, President and Chief Executive Officer of Verrica Pharmaceuticals, will present at the Citizens Life Sciences Conference in New York City. |
globenewswire.com |
2025-04-30 12:00:00 |
Czytaj oryginał (ang.) |
| Verrica Pharmaceuticals Appoints Gavin Corcoran, M.D. to its Board of Directors |
WEST CHESTER, Pa., April 02, 2025 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or the “Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced the appointment of Gavin Corcoran, M.D. |
globenewswire.com |
2025-04-02 20:05:00 |
Czytaj oryginał (ang.) |
| Here's Why Verrica Pharmaceuticals (VRCA) Is a Great 'Buy the Bottom' Stock Now |
Verrica Pharmaceuticals (VRCA) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term. |
zacks.com |
2025-04-01 15:00:54 |
Czytaj oryginał (ang.) |
| Verrica Pharmaceuticals to Participate in the 24th Annual Needham Virtual Healthcare Conference |
WEST CHESTER, Pa., March 31, 2025 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or “the Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that Jayson Rieger, PhD, MBA, President and Chief Executive Officer of Verrica Pharmaceuticals, will participate in a fireside chat at the 24th Annual Needham Virtual Healthcare Conference. |
globenewswire.com |
2025-03-31 12:00:00 |
Czytaj oryginał (ang.) |
| Verrica Pharmaceuticals Appoints Noah L. Rosenberg, M.D. |
WEST CHESTER, Pa., March 26, 2025 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or the “Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced the appointment of Noah L. Rosenberg, M.D., as Chief Medical Officer. |
globenewswire.com |
2025-03-26 09:00:00 |
Czytaj oryginał (ang.) |
| Verrica Pharmaceuticals, Inc. (VRCA) Q4 2024 Earnings Conference Call Transcript |
Verrica Pharmaceuticals, Inc. (NASDAQ:VRCA ) Q4 2024 Earnings Conference Call March 10, 2025 4:30 PM ET Company Participants John Fraunces - Director, Corporate Communications, LifeSci Advisors, IR Jayson Rieger - President and CEO John Kirby - Interim CFO Conference Call Participants Stacy Ku - TD Cowen Gregory Renza - RBC Capital Markets Kemp Dolliver - Brookline Capital Markets Operator Good evening, ladies and gentlemen, and welcome to the Verrica Pharmaceuticals' Fourth Quarter and Full Year 2024 Corporate Update Conference Call. At this time, all participants are in a listen-only mode. |
seekingalpha.com |
2025-03-11 22:30:05 |
Czytaj oryginał (ang.) |
| Verrica Pharmaceuticals Inc. (VRCA) Reports Q4 Loss, Lags Revenue Estimates |
Verrica Pharmaceuticals Inc. (VRCA) came out with a quarterly loss of $0.24 per share versus the Zacks Consensus Estimate of a loss of $0.25. This compares to loss of $0.48 per share a year ago. |
zacks.com |
2025-03-11 20:25:24 |
Czytaj oryginał (ang.) |
| Verrica Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results |
– Company generated quarterly sequential growth in YCANTH® dispensed applicator units of 12.3% in Q4'24 concurrent with significantly lower operating expenses – |
globenewswire.com |
2025-03-11 18:05:00 |
Czytaj oryginał (ang.) |
| Verrica Pharmaceuticals to Report Fourth Quarter and Full Year 2024 Financial Results and Provide a Corporate Update on March 11, 2025 |
WEST CHESTER, Pa., March 03, 2025 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or “the Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that it will host a conference call and live webcast at 4:30 p.m. |
globenewswire.com |
2025-03-03 09:00:00 |
Czytaj oryginał (ang.) |
| Verrica Pharmaceuticals Inc. (VRCA) Expected to Beat Earnings Estimates: Should You Buy? |
Verrica Pharmaceuticals (VRCA) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. |
zacks.com |
2025-02-27 13:06:29 |
Czytaj oryginał (ang.) |
| Verrica Pharmaceuticals to Participate in the TD Cowen 45th Annual Health Care Conference in Boston |
WEST CHESTER, Pa., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or “the Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that Jayson Rieger, PhD, MBA, President and Chief Executive Officer of Verrica Pharmaceuticals, will participate in a fireside chat at the TD Cowen 45th Annual Health Care Conference in Boston. |
globenewswire.com |
2025-02-25 18:05:00 |
Czytaj oryginał (ang.) |
| Verrica Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) |
WEST CHESTER, Pa., Dec. 09, 2024 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or the “Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that Verrica's Compensation Committee granted David Zawitz, Verrica's new Chief Operating Officer, a nonqualified stock option to purchase 950,000 shares of its common stock under the Company's Inducement Plan, effective December 9, 2024. The stock option was granted as a material inducement to Mr. Zawitz's employment with Verrica in accordance with Nasdaq Listing Rule 5635(c)(4). |
globenewswire.com |
2024-12-09 18:15:00 |
Czytaj oryginał (ang.) |
| Verrica Pharmaceuticals Announces that Development Partner Torii Pharmaceutical Files New Drug Application of TO-208 the Treatment of Molluscum Contagiosum in Japan |
WEST CHESTER, Pa., Dec. 06, 2024 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or the “Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced its development and commercialization partner, Torii Pharmaceutical Co. Ltd. (“Torii”), submitted a New Drug Application (“NDA”) of TO-208 (referred to as VP-102 and marketed as YCANTH® in the U.S.) for the treatment of Molluscum Contagiosum (“molluscum”) in Japan. |
globenewswire.com |
2024-12-06 10:00:00 |
Czytaj oryginał (ang.) |
| Verrica Announces Pricing of $42.0 Million Public Offering |
WEST CHESTER, Pa., Nov. 21, 2024 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or the “Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced the pricing of an underwritten public offering of 44,964,045 shares of its common stock and, in lieu of common stock to certain investors that so choose, pre-funded warrants to purchase 2,235,955 shares of its common stock, and in either case, accompanying Series A warrants to purchase 23,600,000 shares of its common stock at an exercise price of $1.0680 per share of common stock and Series B warrants to purchase 23,600,000 shares of its common stock at an exercise price of $1.3350 per share of common stock, at a combined public offering price of $0.89 per share of common stock and accompanying Series A and Series B warrants (or $0.8899 per pre-funded warrant and accompanying Series A and Series B warrants). All of the securities being sold in the offering are being sold by Verrica. The offering is expected to close on November 22, 2024, subject to the satisfaction of customary closing conditions. Verrica also granted the underwriter an option for a period of 30 days to purchase up to 7,080,000 additional shares of the Company's common stock and/or Series A warrants to purchase up to 3,540,000 additional shares of its common stock and Series B warrants to purchase up to 3,540,000 additional shares of its common stock at the public offering price, less the underwriting discounts and commissions. |
globenewswire.com |
2024-11-21 09:30:00 |
Czytaj oryginał (ang.) |
| Verrica Announces Proposed Public Offering |
WEST CHESTER, Pa., Nov. 20, 2024 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or the “Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that it intends to offer and sell shares of its common stock (or pre-funded warrants to purchase its common stock in lieu thereof) and in either case, accompanying warrants to purchase shares of its common stock, in an underwritten public offering. All of the securities in the proposed offering will be sold by Verrica. Verrica intends to grant the underwriter a 30-day option to purchase additional shares of its common stock and/or accompanying warrants to purchase shares of its common stock in an amount up to 15% of the securities offered in the public offering under the same terms and conditions. The proposed offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or the actual size or terms of the offering. |
globenewswire.com |
2024-11-20 18:05:00 |
Czytaj oryginał (ang.) |
| Verrica Pharmaceuticals Inc. Investor Alert (NASDAQ: VRCA): Schubert Jonckheer & Kolbe LLP Investigating Potential Shareholder Claims Against the Company's Officers and Directors for Possible False Statements |
SAN FRANCISCO , Oct. 30, 2024 /PRNewswire/ -- Schubert Jonckheer & Kolbe LLP advises Verrica Pharmaceuticals Inc. investors that the firm is investigating potential legal claims relating to the company's unsuccessful efforts in 2021 and 2022 to secure regulatory approval for its drug product VP-102, designed to treat molluscum. Current shareholders are encouraged to contact the firm. |
prnewswire.com |
2024-10-30 12:00:00 |
Czytaj oryginał (ang.) |
| Verrica Pharmaceuticals Announces Acceptance of Two Abstracts Featuring Positive Preliminary Topline Results of VP-315 for the Treatment of Basal Cell Carcinoma at the 2024 Fall Clinical Dermatology Conference |
- Posters to highlight the safety data, tolerability data, and antitumor efficacy data of VP-315 for the treatment of basal cell carcinoma as determined by histological clearance - |
globenewswire.com |
2024-10-24 11:00:00 |
Czytaj oryginał (ang.) |
| VERRICA PHARMACEUTICALS INVESTIGATION CONTINUED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of Verrica Pharmaceuticals Inc. - VRCA |
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF continues its investigation into Verrica Pharmaceuticals Inc. (NasdaqGM: VRCA). In December 2020, the Company submitted a New Drug Application (“NDA”) to the U.S. Food and Drug Administration (“FDA”) for regulatory approval of its lead product, VP-102 or YCANTH, for the treatment of molluscum contagiosum, a skin disea. |
businesswire.com |
2024-10-11 21:21:00 |
Czytaj oryginał (ang.) |
| Verrica Pharmaceuticals Announces Restructuring of Commercial Organization |
- Company significantly reduces cost structure with a realigned sales, marketing and operational infrastructure - Sales and marketing efforts to focus on pediatricians and expand access beyond dermatologists WEST CHESTER, Pa., Oct. 02, 2024 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or the “Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced a restructuring of its sales and operating teams to reduce costs and expand access to YCANTH ® for the treatment of molluscum contagiosum. |
globenewswire.com |
2024-10-02 11:30:00 |
Czytaj oryginał (ang.) |
| VERRICA PHARMACEUTICALS INVESTIGATION CONTINUED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of Verrica Pharmaceuticals Inc. - VRCA |
NEW ORLEANS , Sept. 27, 2024 /PRNewswire/ -- Former Attorney General of Louisiana, Charles C. |
prnewswire.com |
2024-09-28 02:29:00 |
Czytaj oryginał (ang.) |
| Verrica Pharmaceuticals to Participate in the H.C. Wainwright 26th Annual Global Investment Conference in New York |
WEST CHESTER, Pa., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or “the Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that Ted White, President and Chief Executive Officer of Verrica Pharmaceuticals, will participate in a fireside chat at the H.C. Wainwright 26th Annual Global Investment Conference in New York City. |
globenewswire.com |
2024-09-04 11:30:00 |
Czytaj oryginał (ang.) |
| Verrica Pharmaceuticals, Inc. (VRCA) Q2 2024 Earnings Call Transcript |
Verrica Pharmaceuticals, Inc. (NASDAQ:VRCA ) Q2 2024 Earnings Conference Call August 14, 2024 8:30 AM ET Company Participants Kevin Gardner - Managing Director, LifeSci Advisors Ted White - President and Chief Executive Officer Joe Bonaccorso - Chief Commercial Officer Terry Kohler - Chief Financial Officer Gary Goldenberg - Chief Medical Officer Conference Call Participants Stacy Ku - TD Cowen Gregory Renza - RBC Capital Markets Glen Santangelo - Jefferies Oren Livnat - H.C. Wainwright Serge Belanger - Needham Kemp Dolliver - Brookline Capital Markets Operator Good morning, and welcome to the Verrica Pharmaceuticals Second Quarter 2024 Earnings Conference Call. |
seekingalpha.com |
2024-08-14 20:37:07 |
Czytaj oryginał (ang.) |
| Verrica Pharmaceuticals Inc. (VRCA) Reports Q2 Loss, Tops Revenue Estimates |
Verrica Pharmaceuticals Inc. (VRCA) came out with a quarterly loss of $0.31 per share versus the Zacks Consensus Estimate of a loss of $0.43. This compares to loss of $0.21 per share a year ago. |
zacks.com |
2024-08-14 13:56:10 |
Czytaj oryginał (ang.) |
| Verrica Pharmaceuticals Reports Second Quarter 2024 Financial Results |
- Reports YCANTH ® revenue, net of $4.9M for second quarter of 2024 along with the expansion of YCANTH's distribution footprint to include Cencora, Inc. as a specialty distributor – |
globenewswire.com |
2024-08-14 11:45:00 |
Czytaj oryginał (ang.) |
| Verrica Pharmaceuticals Announces Positive Preliminary Topline Results from Part 2 of Phase 2 Clinical Study of VP-315, an Investigational Oncolytic Peptide-Based Immunotherapy for the Treatment of Patients with Basal Cell Carcinoma |
VP-315 was well tolerated with no reported treatment-related serious adverse events All patients treated with VP-315 had a reduction in tumor size with an overall reduction in tumor size of all lesions treated in Part 2 of approximately 86% Approximately 51% of lesions treated in Part 2 achieved complete histological clearance Patients with residual tumor on average achieved an approximate 71% reduction in tumor size ~3.6 million basal cell carcinomas diagnosed in the U.S. each year, which is expected to continue to grow due to aging US population, better diagnosis and increased exposure to risk factors WEST CHESTER, Pa., Aug. 14, 2024 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or “the Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced preliminary positive results from Part 2 of its Phase 2 clinical trial studying VP-315, a potential first-in-class oncolytic peptide, for the treatment of basal cell carcinoma. |
globenewswire.com |
2024-08-14 11:30:00 |
Czytaj oryginał (ang.) |
| Verrica Pharmaceuticals to Report Second Quarter Financial Results and Release Preliminary Topline Results from Part 2 of Phase 2 Trial of VP-315 for the Treatment of Basal Cell Carcinoma on August 14, 2024 |
WEST CHESTER, Pa., Aug. 06, 2024 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or “the Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that it will host a conference call and live webcast at 8:30 a.m. ET on Wednesday, August 14, 2024, to discuss the Company's financial results for the second quarter ended June 30, 2024, and provide an overview of topline results from Part 2 of the Phase 2 trial of VP-315 for the treatment of basal cell carcinoma. |
globenewswire.com |
2024-08-06 11:30:00 |
Czytaj oryginał (ang.) |
| 7 Short-Squeeze Stocks That Could Beat Down the Bears |
Short-squeeze stocks represent one of the boldest forms of contrarianism available. Simply put, it's a showdown between the bears that are attempting to profit from the downturn of a public enterprise. |
investorplace.com |
2024-07-15 15:57:15 |
Czytaj oryginał (ang.) |
| Verrica Pharmaceuticals Announces Litigation Settlement with Dormer Laboratories, Inc. |
- Dormer Labs has discontinued the sale of all cantharidin-containing products into the United States - YCANTH is the only commercially available, FDA approved therapy for molluscum contagiosum and is clinically proven to be safe and effective WEST CHESTER, Pa., July 01, 2024 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced the settlement of litigation with Dormer Laboratories, Inc. (“Dormer Labs”). |
globenewswire.com |
2024-07-01 11:30:00 |
Czytaj oryginał (ang.) |
| Verrica Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference in New York |
WEST CHESTER, Pa., May 30, 2024 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or “the Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that Ted White, President and Chief Executive Officer of Verrica Pharmaceuticals, will participate in a fireside chat at the Jefferies Global Healthcare Conference in New York City. |
globenewswire.com |
2024-05-30 20:30:00 |
Czytaj oryginał (ang.) |
| Verrica Pharmaceuticals Announces Amendment to Company's Collaboration and License Agreement with Torii Pharmaceutical Co. Ltd. to Fund Global Pivotal Phase 3 Clinical Trial to Study YCANTH® for the Treatment of Common Warts |
Global pivotal Phase 3 clinical trial would be conducted jointly by Verrica and Torii Pharmaceutical; trial expected to begin in the 1 st half of 2025 |
globenewswire.com |
2024-05-15 11:30:00 |
Czytaj oryginał (ang.) |
| Verrica Pharmaceuticals, Inc. (VRCA) Q1 2024 Earnings Call Transcript |
Verrica Pharmaceuticals, Inc. (NASDAQ:VRCA ) Q1 2024 Earnings Conference Call May 13, 2024 8:30 AM ET Company Participants Chris Calabrese - MD, LifeSci Advisors Ted White - President & CEO Joe Bonaccorso - CCO Terry Kohler - CFO Gary Goldenberg - CMO Chris Hayes - Chief Legal Officer Conference Call Participants Stacy Ku - TD Cowen Anish Nikhanj - RBC Capital Markets Glen Santangelo - Jefferies Oren Livnat - H.C. Wainwright Serge Belanger - Needham and Company Kemp Dolliver - Brookline Capital Markets Operator Ladies and gentlemen, good morning, and welcome to the Verrica Pharmaceuticals First Quarter 2024 Earnings Conference Call. |
seekingalpha.com |
2024-05-13 15:49:09 |
Czytaj oryginał (ang.) |